| Assessment Status | Awaiting HTA submission from Applicant |
| HTA ID | 20054 |
| Drug | Carfilzomib (in combination with daratumumab and dexamethasone) |
| Brand | Kyprolis® |
| Indication | In combination with daratumumab and dexamethasone (CAR+DAR+DEX) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. |
| Assessment Process | |
| Rapid review commissioned | 08/12/2020 |
| Rapid review completed | 14/01/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of carfilzomib in combination with daratumumab and dexamethasone compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 27/01/2021 |
| Pre-submission consultation with Applicant | 12/10/2021 |
The company is awaiting additional clinical evidence and has not submitted a HTA dossier to the NCPE. Therefore the cost effectiveness of the technology could not be proven at this time.
